ICAM4

Across TCGA pan-cancer cohorts, ICAM4 Mutation is linked to patient survival in 5 of 34 cancer types, making it the most broadly survival-associated ICAM4 data layer compared with 1 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ICAM4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ICAM4 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, KICH, and UCS are the cancer types where ICAM4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.079	0.812	<.001	24	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCS	OS	Median	II,III,IV	0.007	0.616	<.001	12	view →
PRAD	DFS	Median	All	0.068	0.935	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.943	0.668	.035	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ICAM4–LUAD (OS)

Open the LUAD breakdown →